Trump sets 0% then 100–200% path for generic-drug tariffs

President Donald Trump’s administration will keep tariffs on generic pharmaceuticals at zero for two years starting Aug. 1, then raise them to 100% for one year and 200% after that, Reuters reported, outlining a stepped path for imported generic drugs.

What the tariff schedule provides

According to Reuters, the plan would leave generic drugs free of new tariffs for a two-year period that begins Aug. 1. After that window closes, the duty on covered generic imports would rise to 100% for the following year. Once that year ends, the rate would climb further to 200% and remain at that level under the path described in the reporting.

The timeline and rates were presented in Reuters coverage of the administration’s approach to pharmaceutical trade policy. The summary of that reporting does not spell out every product category or exception that might apply, and details beyond the 0%–100%–200% sequence should be treated as subject to official clarification.

How the phases would work

Under the schedule Reuters described, the first phase is a two-year period of 0% tariffs on generics from the Aug. 1 start date. The second phase would apply a 100% tariff for one year. The third phase would set the rate at 200% thereafter.

That structure would delay the heaviest duties while still signaling much higher charges later. Reuters reported the sequence as the administration’s path for generic-drug tariffs rather than an immediate across-the-board levy at the top rate. Whether the same schedule applies uniformly to all generic products, supply routes, or trading partners was not fully set out in the account summarized for this article.

Context and attribution

The outline comes from Reuters reporting amplified on X and attributed to that wire service as the primary source for the timeline and percentage steps. Other outlets may provide additional confirmation or nuance as official documents and agency guidance are released.

Claims about start dates, duration of the zero-tariff period, and the 100% and 200% steps should be understood as according to Reuters, not as independently verified legislative text or a final Federal Register notice in this write-up. Where official language has not yet been published or fully reviewed, the details remain as reported rather than confirmed as final law.

What remains unclear

Open questions include how “generic” drugs will be defined for tariff purposes, whether active pharmaceutical ingredients and finished dosage forms are treated the same, and how the schedule interacts with existing trade agreements or other pharmaceutical tariff measures. Reuters’ account, as summarized, centers on the multi-year rate path rather than a full regulatory playbook.

Industry reaction, congressional response, and any subsequent White House or Commerce Department fact sheets were not part of the core Reuters summary used here. Readers should watch for formal notices that lock in effective dates, product coverage, and enforcement rules. Until those appear, the story rests on the reported path: zero tariffs on generics for two years from Aug. 1, then 100% for a year, then 200% thereafter, according to Reuters.